News and Press Releases

All | News | Press | Recruitment

Recent | Archive

Valo Therapeutics Announces Positive Interim Results from PeptiCRAd-1 Phase 1 Clinical Trial

Helsinki, Finland, 30 June, 2025 – Valo Therapeutics Oy (ValoTx), a clinical-stage biotechnology company developing novel oncolytic virus-based cancer immunotherapies, today announced encouraging interim results from its ongoing Phase 1 clinical trial, START (Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer) — ClinicalTrials.gov ID: NCT05492682 . PeptiCRAd-1 combines tumor-targeting adenoviruses with tumor-specific peptides to stimulate both innate and adaptive immune responses against cancer. Key Interim Findings (Cohort 1): Well tolerated, with no serious treatment-related adverse reactions. Immune activation

30/6/25

Press Release

ValoTx Appoints Marcella Origgi from Johnson & Johnson Innovation as CEO

Helsinki, Finland and Naples, Italy, 9 April, 2025 – Valo Therapeutics Oy (ValoTx), an immunotherapy company developing novel, adaptable treatments for cancer, today announced the appointment of Marcella Origgi as its Chief Executive Officer (CEO) of its Helsinki headquarters and Naples subsidiary. Marcella joins from Johnson & Johnson Innovation and is an accomplished leader with extensive experience in immuno-oncology, precision medicine, and advanced therapy medicinal products (ATMPs). Marcella’s appointment, based in Italy, comes at a pivotal time for ValoTx, following

8/4/25

Press Release

Valo Therapeutics announces EUR 19m of investment funding and expanded clinical trials

10th March - Helsinki, Finland - Naples, Italy - Perth, Australia Valo Therapeutics Oy announces that it has successfully secured a financing round of €19 million, part of which was raised in Europe and part in Australia, to clinically develop its innovative immune therapy for cancer. An investment round of €13 million was co-led by Indaco Venture Partners and CDP Venture Capital SGR with the support of Fondazione ENEA Tech e Biomedical. They join the completed €6 million investment round

7/3/25

Press Release

Lisata Therapeutics and Valo Therapeutics Announce Preclinical Research Collaboration

Study will investigate the benefits of combining Lisata's novel product candidate, certepetide, with ValoTx's platform technology, PeptiCRAd, and a checkpoint inhibitor in preclinical tumor models

6/11/24

Press Release

Leadership Change

Paul Higham recently resigned as CEO of the company and will leave in May to pursue other opportunities. Sari Pesonen, co-founder and currently Chief Scientific Officer, will take over as CEO in early May. Matti Hautsalo commented on behalf of the Board: 'We would like to thank Paul for his service to the company over the past almost 4 years and wish him well for the future. Sari co-founded the company in 2016 and has led the scientific development of

22/4/24

Press Release

Valo Therapeutics Announces Regulatory Approval to Expand Phase I Immuno-oncology Trial into Sarcoma

Four cancer types now included in PeptiCRAd-1 with Pembrolizumab trial: sarcoma, melanoma, triple negative breast cancer and non-small cell lung cancer

28/11/23

Press Release

Valo Therapeutics Announces Acquisition of Bruker Corporation’s Latest Mass Spectrometer Platform for Tumor Antigen Identification with ValoTx’s PeptiCHIP Technology

Top-of-the-Line Molecular Analytics Instrument with Transformative Sensitivity will enable Rapid Identification of Tumor Antigens

10/10/23

Press Release

Valo Therapeutics and Texcell Announce Research Collaboration to Evaluate Immune Responses to PeptiCRAd-1 in Phase I Clinical Study

Helsinki, Finland & Evry, France, 13 June 2023 – Valo Therapeutics Oy (ValoTx), the developer of novel, adaptable immunotherapies for cancer, announces a collaboration with global contract research organization, Texcell, to investigate immune responses to PeptiCRAd-1 in its Phase 1 clinical study. ValoTx’s PeptiCRAd-1 combines the power of a tumor-specific adenovirus (expressing immune-stimulatory molecules CD40L and OX40L) with immunogenic tumor peptides derived from NY-ESO-1 and MAGE-A3 proteins thereby generating tumor-specific, cytotoxic T-cells that will attack and kill cancer cells. The

13/6/23

Press Release

Valo Therapeutics Announces First Patient Dosed with PeptiCRAd-1 - Innovative Immuno-oncology

Germany based trial of 15 patients with melanoma, triple negative breast cancer or non-small cell lung cancer

23/5/23

Press Release

Valo Therapeutics Announces Two European Patents Granted for its Lead Asset PeptiCRAd-1 in Immuno-Oncology

Helsinki, Finland, 16th Feb, 2023 - Valo Therapeutics Oy (ValoTx), the developer of novel, adaptable immunotherapies for cancer and infectious diseases, announces it has been granted European patents EP3768305 and EP3768830, issued by the European Patent Office (EPO) on 7 February 2023. The patents cover the pharmaceutical composition and method of use for the treatment of cancer for ValoTx’s lead product PeptiCRAd-1 (Peptide-coated Conditionally Replicating Adenovirus-1). These two patents cover its lead virus VALO-D102 and the peptides coating the virus

15/2/23

Press Release

Valo Therapeutics Secures EUR 2.23 million from the European Innovation Council to Progress Innovative PeptiCHIP Technology

Helsinki, Finland, 14th February 2023: Valo Therapeutics Oy (Valo Tx), the developer of novel, adaptable immunotherapies for cancer and infectious diseases, announces that it has secured funding of approximately EUR 2.23 million (around USD 2.42 million) from the European Innovation Council (EIC) for a project to progress the company’s innovative PeptiCHIP technology. PeptiCHIP rapidly identifies a tumor’s antigen presentation profile to drive development of novel personalized immunotherapies. The project, which will be fully funded by the EIC with a 100%

13/2/23

Press Release

Valo Therapeutics selects Exothera to develop large-scale oncolytic Adenovirus manufacturing

Helsinki, Finland, January 11th, 2022 – Valo Therapeutics Oy (ValoTx), the developer of novel, adaptable immunotherapy platforms for cancer and infectious diseases, today announced it has selected Exothera S.A., a full-service Contract Development and Manufacturing Organization (CDMO) specialized in gene therapy, vaccines, and oncolytic viruses, to develop a large-scale manufacturing process for clinical development of its oncolytic adenovirus, VALO-D102. ValoTx’s VALO-D102 oncolytic adenovirus is a fundamental component of the company’s proprietary PeptiCRAd (Peptide-coated Conditionally Replicating Adenovirus) immuno-oncology platform. The platform

11/1/23